Literature DB >> 30225933

Severity in polycystic liver disease is associated with aetiology and female gender: Results of the International PLD Registry.

René M M van Aerts1, Wietske Kievit1, Michiel E de Jong1, Curie Ahn2, Jesús M Bañales3, Jana Reiterová4, Frederik Nevens5, Joost P H Drenth1.   

Abstract

BACKGROUND & AIMS: Polycystic liver disease (PLD) occurs in two genetic disorders, autosomal-dominant polycystic kidney disease (ADPKD) and autosomal-dominant polycystic liver disease (ADPLD). The aim of this study is to compare disease severity between ADPKD and ADPLD by determining the association between diagnosis and height-adjusted total liver volume (hTLV).
METHODS: We performed a cross-sectional analysis with hTLV as endpoint. Patients were identified from the International PLD Registry (>10 liver cysts) and included in our analysis when PLD diagnosis was made prior to September 2017, hTLV was available before volume-reducing therapy (measured on computed tomography or magnetic resonance imaging) and when patients were tertiary referred. Data from the registry were retrieved for age, diagnosis (ADPKD or ADPLD), gender, height and hTLV.
RESULTS: A total of 360 patients (ADPKD n = 241; ADPLD n = 119) met our inclusion criteria. Female ADPKD patients had larger hTLV compared with ADPLD (P = 0.008). In a multivariate regression analysis, ADPKD and lower age at index CT were independently associated with larger hTLV in females, whereas in males a higher age was associated with larger hTLV. Young females (≤51 years) had larger liver volumes compared with older females (>51 years) in ADPKD.
CONCLUSION: Aetiology is presented as a new risk factor associated with PLD severity. Young females with ADPKD represent a subgroup of PLD patients with the most severe phenotype expressed in hTLV.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  ADPKD; ADPLD; polycystic liver disease; risk factors

Mesh:

Year:  2018        PMID: 30225933     DOI: 10.1111/liv.13965

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  7 in total

1.  Tamoxifen for the treatment of polycystic liver disease: A case report.

Authors:  Sophie E Aapkes; Lucas H P Bernts; M van den Berg; Ron T Gansevoort; Joost P H Drenth
Journal:  Medicine (Baltimore)       Date:  2021-08-13       Impact factor: 1.817

Review 2.  Genetics, pathobiology and therapeutic opportunities of polycystic liver disease.

Authors:  Paula Olaizola; Pedro M Rodrigues; Francisco J Caballero-Camino; Laura Izquierdo-Sanchez; Patricia Aspichueta; Luis Bujanda; Nicholas F Larusso; Joost P H Drenth; Maria J Perugorria; Jesus M Banales
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-05-13       Impact factor: 73.082

3.  Estrogen-Containing Oral Contraceptives Are Associated With Polycystic Liver Disease Severity in Premenopausal Patients.

Authors:  René M M van Aerts; Lucas H P Bernts; Tom J G Gevers; Wietske Kievit; Lisanne Koopmans; Theodoor E Nieboer; Frederik Nevens; Joost P H Drenth
Journal:  Clin Pharmacol Ther       Date:  2019-07-23       Impact factor: 6.875

4.  Prevalence of Inferior Vena Cava Compression in ADPKD.

Authors:  Xiaorui Yin; Jon D Blumenfeld; Sadjad Riyahi; Xianfu Luo; Hanna Rennert; Irina Barash; Martin R Prince
Journal:  Kidney Int Rep       Date:  2020-11-01

5.  Protocol for a randomized controlled multicenter trial assessing the efficacy of leuprorelin for severe polycystic liver disease: the AGAINST-PLD study.

Authors:  S E Aapkes; L H P Bernts; A P van den Berg; M van den Berg; H Blokzijl; A E P Cantineau; M D A van Gastel; R J de Haas; P Kappert; R U Müller; F Nevens; R Torra; A Visser; J P H Drenth; R T Gansevoort
Journal:  BMC Gastroenterol       Date:  2022-02-25       Impact factor: 3.067

6.  Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis.

Authors:  Dana Sierks; Ria Schönauer; Anja Friedrich; Elena Hantmann; Jonathan de Fallois; Nikolas Linder; Janett Fischer; Adam Herber; Carsten Bergmann; Thomas Berg; Jan Halbritter
Journal:  JHEP Rep       Date:  2022-09-08

7.  The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials.

Authors:  Carlo Garofalo; Ivana Capuano; Luigi Pennino; Ilaria De Gregorio; Eleonora Riccio; Michele Provenzano; Felice Crocetto; Pasquale Buonanno; Savio Domenico Pandolfo; Michele Andreucci; Antonio Pisani
Journal:  Sci Rep       Date:  2021-12-06       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.